A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously
Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.